YOUNGER people are now candidates for Zostavax to prevent shingles
YOUNGER people are now candidates for Zostavax to prevent shingles.
Zostavax is now approved by FDA for ages 50 and up...instead of just 60 and up. This will also likely be adopted by CDC soon.
This means about 40 million MORE people will be candidates...if you can get the vaccine. Zostavax is still in short supply because Merck is concentrating on making Varivax for chickenpox instead.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote